(Q36903952)

17 August 2017

title

Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. (English)

1 reference

17 August 2017

5

Geoffrey W McCaughan

1 reference

17 August 2017

author name string

David van der Poorten

1

1 reference

17 August 2017

Emilia Prakoso

2

1 reference

17 August 2017

Teh-Liane Khoo

3

1 reference

17 August 2017

Meng C Ngu

4

1 reference

17 August 2017

Simone I Strasser

6

1 reference

17 August 2017

Alice U Lee

7

1 reference

17 August 2017

publication date

6 August 2007

1 reference

Journal of Gastroenterology and Hepatology

17 August 2017

published in

1 reference

17 August 2017

volume

22

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1500-1505

1 reference

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Treatment options in HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Evaluation of abnormal liver-enzyme results in asymptomatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Antiviral drug resistance: clinical consequences and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05093.X

10.1111/J.1440-1746.2007.05093.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference